Independent validation of laboratory test used in PRESEPT Study shows that the test finds 86% of the cancers Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Subtitle: Independent validation ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics BERLIN and SEATTLE - October 22, 2010 (euro adhoc) - Epigenomics AG, the cancer diagnostics company, today announced that it will present ...
Presentation at ASCO - NCI - EORTC Molecular Markers Meeting Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Subtitle: Presentation at ASCO - NCI - EORTC Molecular Markers Meeting Berlin ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Berlin and Seattle, October 18, 2010 (euro adhoc) - ARUP Laboratories, Salt Lake City, UT, USA, a licensee of Epigenomics, will present ...
Epigenomics expands commercial reach for CE-marked product beyond home market Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Subtitle: Epigenomics expands commercial reach for CE-marked ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Berlin, Germany and Surrey, United Kingdom, 6th October, 2010 (euro adhoc) - The cancer molecular diagnostics company Epigenomics AG and ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Press release, Berlin, Germany, and Seattle, WA, U.S.A., September 3, 2010 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company informed, that Geert ...
Key Figures * Revenue: EUR 1.0 million in H1 2010 (H1 2009: EUR 2.1 million) * EBIT: EUR -5.4 million in H1 2010 (H1 2009: EUR -4.8 million) * Net loss: EUR 5.4 million in H1 2010 (H1 2009: EUR 4.8 million) * Liquid assets: EUR 32.3 million as of 30/06/2010 (31/12/2009: EUR 6.1 million) Highlights of the First Half 2010 and year to date * Financial position improved significantly * Broadened ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. New Products/Molecular diagnostics/Partnerships Press release Berlin and Seattle, July 21, 2010 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX) announced that its ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. New Products/Molecular diagnostics 20.07.2010 Berlin and Seattle, July 20, 2010 - Epigenomics AG (ISIN: ...
The Epi proLung BL Reflex Assay complements conventional diagnostic methods Test may identify cancers otherwise missed Epigenomics' second molecular diagnostic product launched in Europe Commercial potential from direct sales as well as licensing and partnering going forward Corporate news transmitted by euro adhoc. The issuer/originator is solely ...
Epi proLung BL Reflex Assay demonstrates outstanding technical and clinical performance in pivotal IVD performance evaluation study Novel test introduced to leading pathologists and Oncologists CE-marking and launch as IVD test expected within the next few weeks Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for ...
Innovative Septin9 blood-test offers new opportunities in colorectal cancer early detection Efficient partnerships between laboratories and Epigenomics in educating physicians and patients Survey shows high level of awareness and acceptance of Septin9 testing among primary care physicians Corporate news ...
Key Figures * Revenue: EUR 0.62 million in Q1 2010 (Q1 2009: EUR 1.24 million) * EBIT: EUR -2.61 million in Q1 2010 (Q1 2009: EUR -2.31 million) * Net loss: EUR -2.59 million in Q1 2010 (Q1 2009: EUR -2.42 million) * Liquid assets: Strengthened balance sheet by financing transaction Highlights of the First Quarter 2010 * Successfully completed ...
mSEPT9 biomarker successfully validated as the first biomarker in blood capable of detecting previously unsuspected colorectal cancers in prospective colorectal cancer screening study Final data to be submitted for publication in top-tier journal The CE marked Epi proColon assay, based on mSEPT9, provides ...
Warnex to offer a laboratory-developed blood testing service based on Epigenomics' Septin9 Biomarker Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Licensing Agreements/Molecular diagnostics Subtitle: Warnex to offer a ...
Patent covers detection of colorectal cancer with Septin9 Biomarker Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Patents, Copyright & Trademarks/Molecular diagnostics Subtitle: Patent covers detection of colorectal cancer with Septin9 Biomarker Press release, Berlin, Germany, and ...
Company for the first time supported prestigious award for achievement in colorectal cancer screening Epigenomics' Septin9 blood test for colorectal cancer early detection available in Germany since October 2009 Research study aimed at enhancing blood test to detect precursor lesions nominated for the award Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content ...
Key financials improved significantly in 2009 Important development and commercialization milestones met in 2009 Expect revenue growth and similar earnings in 2010 Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company ...
European diagnostic laboratory network synlab has started offering Septin9 blood testing through its 55 German sites synlab to measure Septin9 using Epi proColon kit on Applied Biosystems 7500 Fast Real-time PCR System; CE-marked kit now also validated for this instrument Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/Molecular diagnostics 30.03.2010 Berlin, Germany, March 30, 2010 - Epigenomics AG (Frankfurt ...
Not for distribution in the United States of America Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/Molecular diagnostics Subtitle: Not for distribution in the United States of America Berlin, Germany, and Seattle, WA, USA, March 25, 2010 (euro adhoc) - ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Financial Figures/Balance Sheet/Molecular diagnostics Press release, Berlin, Germany, and Seattle, WA, U.S.A., March 12, 2010 (euro adhoc) - Key Figures and Financial Highlights: * Full year revenue increased to EUR 4.3 million * ...
Patent broadly covers HeavyMethyl, a core technology of Epigenomics molecular diagnostic products Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Patents, Copyright & Trademarks/Molecular diagnostics Subtitle: Patent broadly covers HeavyMethyl, a core technology of Epigenomics ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/Molecular diagnostics 08.03.2010 Not for distribution in the United States Berlin, Germany, ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/Molecular diagnostics/Studies 08.03.2010 Berlin, March 8, 2010 - Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, ...
New IVD test expected to be launched in Q2 2010 Test supports accurate diagnosis of lung cancer in suspicious cases Conference presentations on scientific evidence and clinical utility Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. New Products/Molecular diagnostics/ ...
Colorectal cancer test Epi proColon now available nationwide in Germany and Switzerland four months after product launch Epigenomics to present recent clinical data at 29th German Cancer Congress (Deutscher Krebskongress) in Berlin, Germany Corporate news transmitted by euro adhoc. The issuer/originator ...
Differences in analytical instrument read-out requires verification and potential retesting of samples measured in laboratory with deviating results Top-line data expected still in Q1 2010 No impact on commercial strategy expected Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/Molecular diagnostics 15.01.2010 Berlin, January 15, 2010 - Epigenomics AG (ISIN: ...